Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure has established a dedicated U.S. CNS Cancers Franchise to enhance its glioblastoma (GBM) business. Frank Leonard, previously Chief Development Officer, has been appointed President of this new unit. The organization aims to improve resource allocation and streamline decisions across the U.S. CNS operations, focusing on delivering Tumor Treating Fields therapy to more GBM patients. CEO Asaf Danziger expressed confidence in Leonard’s leadership and the company’s ongoing mission to extend survival for aggressive cancer types.
Novocure (NASDAQ: NVCR) announced participation in two investor conferences: the Wells Fargo Healthcare Conference on September 7, 2022, with a fireside chat at 4:20 p.m. EDT, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. Executive Chairman William Doyle and CFO Ashley Cordova will lead discussions, with Cordova joined by CMO Ely Benaim for additional meetings. A live audio webcast of the presentations will be available on Novocure’s Investor Relations page, with replays for 14 days.
Novocure focuses on extending survival for aggressive cancers through Tumor Treating Fields.
On August 9, U.S. Senator Maggie Hassan toured Novocure's U.S. headquarters in Portsmouth, New Hampshire, discussing the company's innovative cancer treatments. Hassan emphasized the importance of expanding access to medical technologies and acknowledged Novocure's role as a job creator in New Hampshire. Novocure, headquartered in Switzerland, focuses on extending survival for patients with aggressive cancers through Tumor Treating Fields therapy, with products approved for glioblastoma and malignant pleural mesothelioma. The company also conducts trials for various other cancers.
Novocure (NASDAQ: NVCR) reported net revenues of $140.9 million for Q2 2022, marking a 6% year-over-year increase. While the company made significant progress with data releases from its gastric cancer pilot study and a pivotal trial collaboration with Merck, it also faced challenges in Germany due to reduced patient numbers and updated coverage criteria. The company's gross margin stood at 80%, but it reported a net loss of $24 million with a loss per share of $0.23. Cash reserves totaled $948.5 million as of June 30, 2022.
Novocure announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program, aimed at advancing research on TTFields. The grants, totaling $250,000 over two years, support innovative research efforts, including studies led by Professor Wafik El-Deiry at Brown University, focusing on combining TTFields with other therapies like ONC201. These collaborations aim to deepen understanding of TTFields' mechanisms and enhance treatment strategies for aggressive cancers, aligning with Novocure's commitment to improving cancer care.
Novocure (NASDAQ: NVCR) will report its Q2 2022 financial results on July 28, 2022, prior to U.S. market opening. A conference call will take place at 8 a.m. EDT on the same day to discuss the results. Currently, Novocure is focused on extending survival rates in aggressive cancers through its Tumor Treating Fields technology, approved for glioblastoma and malignant pleural mesothelioma. The company's pipeline includes clinical trials for various cancers, enhancing its global presence and market potential.
Novocure (NASDAQ: NVCR) has enrolled its first patient in the phase 2 KEYNOTE-B36 study, conducted with MSD, to evaluate Tumor Treating Fields (TTFields) alongside KEYTRUDA® for treating advanced non-small cell lung cancer (NSCLC). The study aims to enroll 66 patients and will assess the objective response rate as its primary endpoint, with secondary endpoints including overall survival and adverse event frequency. Lung cancer is the leading cause of cancer death globally, with NSCLC comprising 85% of cases. Novocure's TTFields technology aims to enhance standard cancer therapies.
Novocure (NASDAQ: NVCR) and Zai Lab (NASDAQ: ZLAB) announced promising results from their EF-31 phase 2 study on Tumor Treating Fields (TTFields) combined with the XELOX chemotherapy regimen for gastric adenocarcinoma. The study achieved a confirmed objective response rate of 50%, with a median progression-free survival of 7.8 months and a duration of response of 10.3 months. The one-year survival rate stood at 72%. TTFields therapy demonstrated good tolerability, with no significant increase in systemic toxicity. These results pave the way for future clinical studies.
Novocure (NASDAQ: NVCR) announced a clinical trial collaboration with MSD to study Tumor Treating Fields (TTFields) combined with KEYTRUDA for newly diagnosed glioblastoma (GBM) patients. This collaboration builds on previous positive results from the 2-THE-TOP phase 2 pilot study, which showed median overall survival of 25.2 months. The new trial will be double-blind and placebo-controlled, aiming to enhance treatment options for aggressive cancers. Novocure plans to engage with the FDA regarding the study details soon.
Novocure reported Q1 2022 net revenues of $137.5 million, marking a 2% increase from Q1 2021, with an 80% gross margin. The company aims for a transformational year with significant clinical milestones anticipated, including data releases from multiple studies and the completion of its third pivotal study within 12 months. Despite a net loss of $4.6 million and a loss per share of $0.04, investments in marketing and clinical trials suggest future growth potential.